A Phase 3 interventional study of Coherex WaveCrest® Left Atrial Appendage Occlusion System and Watchman® LAA Closure Device in Stroke, sponsored by Coherex Medical. Terminated at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Coherex Medical (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Stroke by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Stroke · Johnson & Johnson.
Among the 14 studies in Stroke by Johnson & Johnson, this one is one of 2 that started in 2017, is one of 5 in phase 3, and was the 11th registered.
8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.
Browse Stroke studies →None of the 14 studies in Stroke by Johnson & Johnson is open now. The open studies under Stroke, anywhere →
Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 49 across 6,043 interventional studies indexed under Stroke.
Median enrollment 248 across the 9 interventional studies, 2,000 across the 5 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Coherex Medical, one of the names counted as Johnson & Johnson. Under that name alone:
Coherex Medical is the lead sponsor of 4 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Stroke by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System. Subjects will be randomized in a 1:1 ratio to the Treatment Arm (Coherex WaveCrest LAA occlusion system) or the Control Arm (Boston Scientific's Watchman LAA occlusion system). The trial is designed to demonstrate that safety and effectiveness of the WaveCrest device are non-inferior to the Watchman device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Echocardiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WaveCrest left atrial appendage occluder
Device: Coherex WaveCrest® Left Atrial Appendage Occlusion System
Watchman left atrial appendage closure device
Device: Watchman® LAA Closure Device
Percutaneous left atrial appendage closure
Percutaeous left atrial appendage closure
Percentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding
The primary safety outcome was the composite of death from any cause (all-cause mortality), procedure or device related complications requiring percutaneous or surgical intervention through 45 days post procedure or major bleeding throughout the duration of the trial. The analysis was based on sponsor assessment of adverse events data. Baseline was defined as 90 day prior to treatment or 90 days prior to randomization; baseline assessments could occur on the day of implant.
Time frame: All death, procedure- or device-related complications requiring percutaneous or surgical intervention: From baseline up to 45 days; major bleeding: From baseline up to 5 years 11 months
Percentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months
Percentage of participants with composite of ischemic stroke or systemic embolism at 24 months was reported.
Time frame: At 24 months
Percentage of Participants With Ischemic Stroke or Systemic Embolism With the WAVECREST Device in Comparison to the CHADS2 and CHA2DS2-VASc Imputed Risk of Ischemic Stroke or Systemic Embolism in the Absence of Anticoagulant Therapy
CHADS2 (congestive heart failure, hypertension, age \>=75 years (yrs), prior Stroke/transient ischemic attack (TIA)/Thromboembolism) and CHA2DS2-VASc scores (Vascular disease, Age 65- 74 yrs, female Sex) were developed to identify non-valvular atrial fibrillation (AF) participants at an elevated risk for ischemic stroke. CHADS2 score assign 1 point: congestive heart failure, hypertension, age \>= 75 yrs, diabetes mellitus; 2 points: prior stroke/TIA/thromboembolism. CHADS2 score ranges from 0 to 6. Higher scores indicated higher risk for ischemic strokes. CHA2DS2-VASc Score assign 1 point for each following risk factors: congestive heart failure, hypertension (blood pressure consistently above 140/90), diabetes mellitus, vascular disease, age 65 to74 yrs, female and assigned 2 points for age \>=75 yrs and prior stroke or TIA or thromboembolism each. Overall score ranged from 0 to a 9, with lower scores indicated lower risk and higher scores indicated higher risk for ischemic strokes.
Time frame: At 45 days
Percentage of Participants With Left Atrial Appendage (LAA) Closure
Percentage of participants with LAA closure, defined as a gap of \<= 5 millimetre (mm) at the 45-day visit as assessed by transesophageal echocardiogram (TEE) was reported.
Time frame: At 45 days
Analysis population included participants greater than or equal to (\>=) 18 years old diagnosed with non-valvular atrial fibrillation and a CHADS2 score \>= 2 or a CHA2DS2-VASc score \>= 3 who had an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation.
| Milestone | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Started | 71 | 54 | 58 |
| Treated | 71 | 52 | 56 |
| Completed | 6 | 1 | 3 |
| Not completed | 65 | 53 | 55 |
| Withdrew: Other | 7 | 4 | 6 |
| Withdrew: Withdrawal by subject | 10 | 2 | 9 |
| Withdrew: Study terminated by sponsor | 32 | 29 | 30 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 | 3 |
| Withdrew: Death | 13 | 11 | 4 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Randomized but not treated and discontinued during study hold | 0 | 2 | 2 |
The primary safety outcome was the composite of death from any cause (all-cause mortality), procedure or device related complications requiring percutaneous or surgical intervention through 45 days post procedure or major bleeding throughout the duration of the trial. The analysis was based on sponsor assessment of adverse events data. Baseline was defined as 90 day prior to treatment or 90 days prior to randomization; baseline assessments could occur on the day of implant.
| Percentage of participants | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Percentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding | 47.89 (35.9 to 60.1) | 32.69 (20.3 to 47.1) | 17.86 (8.9 to 30.4) |
Percentage of participants with composite of ischemic stroke or systemic embolism at 24 months was reported.
| Percentage of participants | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Percentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months | 4.23 (0.9 to 11.9) | 3.85 (0.5 to 13.2) | 5.36 (1.1 to 14.9) |
CHADS2 (congestive heart failure, hypertension, age \>=75 years (yrs), prior Stroke/transient ischemic attack (TIA)/Thromboembolism) and CHA2DS2-VASc scores (Vascular disease, Age 65- 74 yrs, female Sex) were developed to identify non-valvular atrial fibrillation (AF) participants at an elevated risk for ischemic stroke. CHADS2 score assign 1 point: congestive heart failure, hypertension, age \>= 75 yrs, diabetes mellitus; 2 points: prior stroke/TIA/thromboembolism. CHADS2 score ranges from 0 to 6. Higher scores indicated higher risk for ischemic strokes. CHA2DS2-VASc Score assign 1 point for each following risk factors: congestive heart failure, hypertension (blood pressure consistently above 140/90), diabetes mellitus, vascular disease, age 65 to74 yrs, female and assigned 2 points for age \>=75 yrs and prior stroke or TIA or thromboembolism each. Overall score ranged from 0 to a 9, with lower scores indicated lower risk and higher scores indicated higher risk for ischemic strokes.
| Percentage of participants | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| ischemic strokes | 4.23 | 3.85 | 5.36 |
| systemic embolisms | 0 | 0 | 0 |
Percentage of participants with LAA closure, defined as a gap of \<= 5 millimetre (mm) at the 45-day visit as assessed by transesophageal echocardiogram (TEE) was reported.
| Percentage of participants | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Percentage of Participants With Left Atrial Appendage (LAA) Closure | 100.0 | 100.0 | 100.0 |
Collected over Baseline up to 5 years 11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (WaveCrest Roll-In): | 15/71 (21.1%) | 50/71 (70.4%) | 63/71 (88.7%) |
| Group 2 (WaveCrest Randomized) | 13/52 (25%) | 42/52 (80.8%) | 51/52 (98.1%) |
| Group 3 (Watchman Randomized) | 4/56 (7.1%) | 39/56 (69.6%) | 48/56 (85.7%) |
| Event | Group 1 (WaveCrest Roll-In): | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 11/71 | 7/52 | 5/56 |
| Pericardial effusionCardiac disorders | 9/71 | 2/52 | 1/56 |
| Acute kidney injuryRenal and urinary disorders | 9/71 | 1/52 | 0/56 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/71 | 3/52 | 7/56 |
| Cardiac failure congestiveCardiac disorders | 6/71 | 6/52 | 6/56 |
| PneumoniaInfections and infestations | 7/71 | 6/52 | 6/56 |
| AnaemiaBlood and lymphatic system disorders | 7/71 | 2/52 | 3/56 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 7/71 | 4/52 | 3/56 |
| Urinary tract infectionInfections and infestations | 3/71 | 4/52 | 3/56 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/71 | 4/52 | 2/56 |
| Event | Group 1 (WaveCrest Roll-In): | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) |
|---|---|---|---|
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 14/71 | 13/52 | 10/56 |
| Gastrointestinal disordersGastrointestinal disorders | 15/71 | 10/52 | 13/56 |
| Pericardial effusionCardiac disorders | 11/71 | 12/52 | 12/56 |
| Atrial fibrillationCardiac disorders | 13/71 | 8/52 | 4/56 |
| Corona virus infectionInfections and infestations | 9/71 | 9/52 | 5/56 |
| Urinary tract infectionInfections and infestations | 10/71 | 5/52 | 9/56 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/71 | 6/52 | 8/56 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 11/71 | 4/52 | 5/56 |
| Acute kidney injuryRenal and urinary disorders | 9/71 | 2/52 | 6/56 |
| Chest painGeneral disorders | 8/71 | 5/52 | 7/56 |
The modified intention-to-treat (mITT) analysis set consisted of all randomized participants who had vascular access attempted for the implant procedure of the intended left atrial appendage (LAA) occlusion device.
| Age, Continuous(years) | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) | Total |
|---|---|---|---|---|
| Mean | 72.0 ± 9.64 | 75.9 ± 6.43 | 76.0 ± 5.69 | 74.4 ± 7.88 |
| Sex: Female, Male(Participants) | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) | Total |
|---|---|---|---|---|
| Female | 32 | 21 | 20 | 73 |
| Male | 39 | 31 | 36 | 106 |
| Race/Ethnicity, Customized(Participants) | Group 1 (WaveCrest Roll-In) | Group 2 (WaveCrest Randomized) | Group 3 (Watchman Randomized) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 4 |
| White | 69 | 51 | 53 | 173 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2023, 71 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.